stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Revenue growth
Halozyme Therapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was 45.0%, up 7.5 percentage points from fiscal 2025 (37.6%). Over the past ten years it has ranged from −52.0% (fiscal 2018) to 115.8% (fiscal 2017); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 37.6% | 15.11 |
| FY2024 | 22.4% | (3.18) |
| FY2023 | 25.6% | (23.29) |
| FY2022 | 48.9% | (16.76) |
| FY2021 | 65.7% | 29.14 |
| FY2020 | 36.5% | 7.47 |
| FY2019 | 29.1% | 81.10 |
| FY2018 | −52.0% | (167.88) |
| FY2017 | 115.8% | 107.23 |
| FY2016 | 8.61% | (70.67) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 39.2% | (8.52) |
| Jun 2026 | 47.7% | 5.44 |
| Mar 2026 | 42.2% | (9.37) |
| Dec 2025 | 51.6% | 29.48 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | 167.3% |
| KYMR Kymera Therapeutics, Inc. compare | 134.8% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| HALO Halozyme Therapeutics, Inc. | 45.0% |
| BMRN BioMarin Pharmaceutical Inc. compare | 18.1% |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.5% |
| EXEL Exelixis, Inc. compare | 9.12% |
| TECH Bio-Techne Corp compare | −0.38% |
| SMMT Summit Therapeutics PLC compare | −61.0% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement